Atlas Trials

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Clinical trial NCT06740526 · RECRUITING

Trial details

NCT number
NCT06740526
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
IgA Nephropathy
Start date
2024-11-19
Primary completion
2029-04-17
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.